Robert Doyle

Laura J. and L. Douglas Meredith Professor - Director of Graduate Studies Associate Chair - Department of Chemistry Syracuse University; Associate Professor of Medicine - SUNY, Upstate Medical University Chemistry

Research Interests

Medicinal chemistry, target validation, biochemistry

Professor Doyle's full CV can be found here.

Education and Employment

  • B.A., 1998, Trinity College, Dublin, Ireland
  • Ph.D., 2002, Trinity College, Dublin, Ireland
  • Postdoctoral Fellow, 2002-2003, Australian National University
  • Postdoctoral Fellow, 2003-2005, Yale University
  • Joined Syracuse University Faculty, August 2005
  • Tenure and promotion to Associate Professor 2010
  • Full Professor 2014
  • Laura J. and L. Douglas Meredith Professor 2016

Honors & Awards

  • Enterprise Ireland Fellowship, 1998
  • RSC Fellowship, 2002
  • Rudolph Anderson Foundation Fellowship, 2004
  • Ewing Marion Kauffman Foundation Award, 2008
  • ACS New Investigator Award, 2009
  • Tenure, February 2009
  • Faculty of 1000, Associate Member 2010
  • James K. Duah-Agyeman Award for Outstanding Faculty, 2011
  • Faculty Advisor of the Year, 2012
  • CNY College Educator of the Year, 2013
  • Promoted to Full Professor, 2014
  • Laura J. and L. Douglas Meredith Professor 2016


  • CHE 103: Chemistry in the Modern World
  • CHE 106: General Chemistry
  • CHE 139: Honors General Chemistry
  • CHE 412/612: Metals in Medicine
  • CHE 422/622: Advanced Inorganic Laboratory
  • CHE 450: Independent Research
  • CHE 400/600: Chemical Biology
  • CHE 412/612: Metals in Biology & Medicine

Research Focus

The Doyle group are medicinal chemists that focus on drug devleopment, targeting and toxicity as well as target validation and platform technlogy development for pharmocokinetic improvement of therapeutics.

We are interested in three main areas:

1. Utilizing the vitamin B12 dietary pathway to improve drug delivery, impact drug pharmacokinetics and modify brain uptake and localization. 

     As part of this project we also developi new peptide agonists of the appetite suppressing receptor NPY2-R and glucoregulatory receptor GLP1-R to simulatenously treat obesity and diabetes.

2. Exploring the implications of human lysosomal saposin B protein on drug toxicity and conversely the effects of drug (e.g chloroquine; A2E; atovoquone) binding on saposin B dependent lipid hydrolysis and subsequent lipidosis.

3. Developing new leads for overcoming Mycobacterial resistance to front line pharmamceuticals focusing on unique M. tuberculosis receptors to gain tailored and specific entry to Mtb, including phagolysosomal Mtb.

Selected Publications

View all Publications


Doyle pub

*Conjugate of Insulin and Vitamin B12 for Oral Delivery 1. US 2008-0242595 A1; 2. U.S. 2011-0092416A1
*Vitamin B12- Peptide Conjugate as Therapeutic Agent for Obesity US 2011-0092416 A1
* Methods for the delivery of zinc through use of intrinsic factor or haptocorrin US 14/891,412 
* (Method of use) Vitamin B12-conjugates of exendin-4 removes nausea and maintains glucoregulation (Filed 2016)